Meeting
2022 ASCO Annual Meeting
Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting multifunctional immune-recruitment protein, in patients with advanced solid tumors.
Authors
Jason J. Luke
University of Pittsburgh, Pittsburgh, PA
Jason J. Luke , Anwaar Saeed , Babar Bashir , Yaffa Shwartz , Rinat Tabakman , Adam Foley-Comer , Antonio Jimeno
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other Checkpoint Inhibitors (Non-PD1/PDL1, Monotherapy, or Combination)
Clinical Trial Registration Number
NCT04440735
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2647)
DOI
10.1200/JCO.2022.40.16_suppl.2647
Abstract #
2647
Poster Bd #
301
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting fusion protein, in combination with atezolizumab in patients with advanced solid tumors.
First Author: Anwaar Saeed
Poster
2023 ASCO Annual Meeting
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Judy S. Wang
Poster
2023 ASCO Annual Meeting
Phase 1 dose escalation study of SL-172154 (SIRPα-Fc-CD40L) in platinum-resistant ovarian cancer.
First Author: Nehal J. Lakhani
Poster
2022 ASCO Annual Meeting
Safety, pharmacokinetics, and clinical activity of OBI-3424, an AKR1C3‑activated prodrug, in patients with advanced or metastatic solid tumors: A phase 1 dose-escalation study.
First Author: Apostolia Maria Tsimberidou